There was a trend toward a reduction in the development of breakthrough HE among patients receiving the probiotic ( 34.8 % in the probiotic group vs 51.6 % in the placebo group ; hazard ratio [ HR ] , 0.65 ; 95 % confidence interval [ CI ] , 0.38-1 .11 ; P = .12 ) .